Footnotes, Figure 5.6.4-A 
1 Group 1, n - 2, 
Group 2, n - 2, 
Group 3 , n - 2 , 
Group 4, n - 2, 
Group 5 , n - 2 , 
10 6 pfu/ml, 
10 8 pfu/ml, 
10 9 pfu/ml, 
10 10 pfu/ml, 
10 11 pfu/ml, 
0.2 ml/nostril, 
0.2 ral/nostril, 
0.2 ml/nostril, 
0.2 ml/nostril, 
0.2 ml/nostril, 
20 ml/bronchus 
20 ml/bronchus 
20 ml/bronchus 
20 ml/bronchus 
20 ml/bronchus 
2 The n - 2 individuals in each group will be treated in parallel; subsequent 
groups will enter the protocol 2 weeks after administration of AdCFTR to the 
preceding group if no adverse reactions have been observed (see section 
5.6.6) and no adenovirus can be detected in nasal, pharynx, blood, rectal or 
urine cultures of the preceding group on 3 separate days. 
3 Administration of AdCFTR will be to the left nostril and left bronchus 
(with the right nostril and bronchus as controls) unless anatomic/clinical 
reasons suggest the opposite side is better; if so, AdCFTR will be adminis- 
tered to the right side and the left side will be the control. 
9 For definitions and details, see section 5.5; ■ = test to be performed; 
□ = test optional. 
5 On day 1, samples at 4 hr, 8 hr ; on day 2, samples at 4 hr, 8 hr. 
6 "18-24" = evaluation at months 18 and 24; "years" = yearly evaluation 
starting at year 3. 
[770] 
Recombinant DNA Research, Volume 16 
